Chemotherapy combined with target therapy using antibodies against tumor cell membrane antigens may greatly increase the survival of cancer patients. Similar to autoantigens in autoimmunity diseases, certain membrane components may be more heterogeneous and create new determinants of antigens or haptens after chemotherapy. The aim of the current study was to prepare anti-membrane antibodies against colon carcinoma cells undergoing chemotherapy and examine their anticancer activities in vitro.
Methods
After the colon carcinoma cells were treated by mimic chemotherapy, the synthesized poly-lysine was used as a carrier to link the membrane antigen or hapten with the covalent bond of carbodiimide bridging. It was affirmed by fluorescence-activated cell sorting under laser confocal microscopy that the vaccine with poly-lysine membrane-linked cells with a covalent bond was successfully engineered. Then, the cognate mice were vaccinated, and the anti-membrane polyclonal antibodies were prepared and validated for their activities.
Results
The anti-membrane polyclonal antibodies were effectively induced and prepared. Folliculus lymphaticus were found significantly increased in vaccinated mice, and B lymphocyte proliferation was also intensively stimulated by vaccine and generating antibodies. The polyclonal antibodies, exhibiting minimal endotoxicity, displayed intensive sensitivity, high affinity and strong specificity. They also elicited apoptosis and necrosis for wild type colon carcinoma cells and offered synergistic effect to repress the chemotherapy-resistant tumor cells.
Conclusions
The poly-lysine-linked membrane for colon carcinoma cells undergoing chemotherapy could produce the anti-membrane polyclonal antibodies (promising as novel antibody molecules for target therapy) and generate an effective immune attack on the surviving cancer cells.
CollinsI., WorkmanP.: New approaches to molecular cancer therapeutics.Nat Chem Biol, 2: 689–700, 2006.
4.
LeveneA.P., SinghG., PalmieriC.: Therapeutic monoclonal antibodies in oncology.J R Soc Med, 98: 146–152, 2005.
5.
GorczynskiR.M., ChenZ., DiaoJ., KhatriI., WongK., YuK., BehnkeJ.: Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice.Breast Cancer Res Treat, 123: 405–415, 2010.
6.
AdamsonP.J., ZolaH., NicholsonI.C., PilkingtonG., HohmannA.: Antibody against CD20 in patients with B cell malignancy.Leuk Res, 25: 1047–1050, 2001.
7.
LivingstonP.O., RagupathiG., MusselliC.: Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues.J Clin Immunol, 20: 85–93, 2000.
8.
ObeidM., TesniereA., GhiringhelliF., FimiaG.M., ApetohL., PerfettiniJ.L., CastedoM., MignotG., PanaretakisT., CasaresN., MétivierD., LarochetteN., van EndertP., CiccosantiF., PiacentiniM., ZitvogelL., KroemerG.: Calreticulin exposure dictates the immunogenicity of cancer cell death.Nat Med, 13: 28–30, 2007.
9.
FolliF., PeregoL., PonzoniM., GirardiA.M., BosiE., FerreriA.J., BelloneM., SabbadiniM.G., VicariA.M., TrusolinoL.: Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjögren's syndrome and gastric MALT lymphoma.Ann Hematol, 81: 597–602, 2002.
10.
PetersA.L., StunzL.L., MeyerholzD.K., MohanC., BishopG.A.: Latent membrane protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice.J Immunol, 185: 4053–4062, 2010.
11.
WillcoxN., LeiteM.I., KadotaY., JonesM., MeagerA., SubrahmanyamP., DasguptaB., MorganB.P., VincentA.: Autoimmunizing mechanisms in thymoma and thymus.Ann N Y Acad Sci, 1132: 163–173, 2008.
12.
SrinivasanR., HoughtonA.N., WolchokJ.D.: Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue.Cancer Immunol, 2: 8, 2002.
13.
TüzünE., ErdaE., DurmusH., BrennerT., TürkogluR., KürtüncüM., LangB., Akman-DemirG., EraksoyM., VincentA.: Autoantibodies to neuronal surface antigens in thyroid antibody-positive and -negative limbic encephalitis.Neurol India, 59: 47–50, 2011.
14.
AlfonsoM., DíazA., HernándezA.M., PérezA., RodríguezE., BittonR., PérezR., VázquezA.M.: An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients.J Immunol, 168: 2523–2529, 2002.
RamM., ShoenfeldY.: Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?Ann N Y Acad Sci, 1110: 410–425, 2007.
17.
SinghK.V., KhannaP., SuriC.R., GargM.L.: Structural and immunogenic effects of multiple hapten loading on carrier protein.J AOAC Int, 93: 59–65, 2010.
18.
SchellenbergerM.T., GrovaN., WillièmeS., FarinelleS., ProdhommeE.J., MullerC.P.: Modulation of benzo[a]pyrene induced immunotoxicity in mice actively immunized with a B[a]P-diphtheria toxoid conjugate.Toxicol Appl Pharmacol, 240: 37–45, 2009.
19.
ReillyR.T., EmensL.A., JaffeeE.M.: Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?Curr Opin Investig Drugs, 2: 133–135, 2001.
20.
BaxevanisC.N., PerezS.A., PapamichailM.: Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.Cancer Immunol Immunother, 58: 317–324, 2009.
21.
AveryD.T., KalledS.L., EllyardJ.I., AmbroseC., BixlerS.A., ThienM., BrinkR., MackayF., HodgkinP.D., TangyeS.G.: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.J Clin Invest, 112: 286–297, 2003.
22.
Heltemes-HarrisL., LiuX., ManserT.: Progressive surface B cell antigen receptor down-regulation accompanies efficient development of antinuclear antigen B cells to mature, follicular phenotype.J Immunol, 172: 823–833, 2004.
23.
Chianese-BullockK.A., WoodsonE.M., TaoH., BoernerS.A., SmolkinM., GroshW.W., NeeseP.Y., MerrillP., PetroniG.R., SlingluffC.L.Jr.: Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.J Immunother, 28: 412–419, 2005.
24.
HansenW., WestendorfA.M., BuerJ.: Regulatory T cells as targets for immunotherapy of autoimmunity and inflammation.Inflamm Allergy Drug Targets, 7: 217–223, 2008.
25.
BoulterJ.M., JakobsenB.K.: Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens.Clin Exp Immunol, 142: 454–460, 2005.
26.
BerdD., SatoT., MaguireH.C.Jr., KairysJ., MastrangeloM.J.: Immunopharmacologic analysis of an autologous hapten-modified human melanoma vaccine.J Clin Oncol, 22: 403–415, 2004.
27.
BerdD.: M-Vax: an autologous hapten-modified vaccine for human cancer.Expert Rev Vaccines, 3: 521–527, 2004.
28.
UedaK., NakanishiT., ShimizuA., TakuboT., MatsuuraN.: Identification of L-plastin autoantibody in plasma of patients with non-Hodgkin's lymphoma using a proteomics-based analysis.Ann Clin Biochem, 45: 65–69, 2008.
29.
DalmauJ., BatallerL.: Limbic encephalitis: the new cell membrane antigens and a proposal of clinical-immunological classification with therapeutic implications.Neurologia, 22: 526–537, 2007.
30.
VincentA.: Autoimmune channelopathies: well-established and emerging immunotherapy-responsive diseases of the peripheral and central nervous systems.J Clin Immunol, 30: 97–102, 2010.
31.
Ben-SmithA., DoveS.K., MartinA., WakelamM.J., SavageC.O.: Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fcgamma receptor ligation.Blood, 98: 1448–1455, 2001. [Article in Spanish]
32.
RauschM.P., IrvineK.R., AntonyP.A., RestifoN.P., CresswellP., HastingsK.T.: GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.J Immunol, 185: 2828–2835, 2010.
33.
VincentA., IraniS.R.: Caspr2 antibodies in patients with thymomas.J Thorac Oncol, 5(10 Suppl 4): S277–280, 2010.
